Document is current
Any future updates will be listed below
-
Authors
Woo, Sungmin https://orcid.org/0000-0001-8459-8369
Becker, Anton S.
Leithner, Doris
Mayerhoefer, Marius E.
Friedman, Kent P.
Tong, Angela
Wise, David R.
Taneja, Samir S.
Zelefsky, Michael J.
Vargas, Hebert A.
- License Information
-
More Information
Article History
Received: 30 July 2024
Revised: 7 December 2024
Accepted: 13 December 2024
First Online: 24 January 2025
Compliance with ethical standards
:
: The scientific guarantor of this publication is Sungmin Woo.
: The authors of this manuscript declare relationships with the following companies: Marius E. Mayerhoefer received honoraria for lectures from Siemens, GE, and BM but unrelated to the current work. Kent P. Friedman is a co-investigator on “Optimizing timing of rhPSMA-7.3 (18F), for assessing site(s) of recurrent disease following radical prostatectomy” (PI Herbert Lepor) but does not receive any salary support and is unrelated to the current work. David R. Wise has received consulting fees from Leap Therapeutics, Foundation Medicine, Pfizer, Janssen, Sanofi, Lilly, Labcorp, Myovant, Bayer, AstraZeneca, Accutar and has received travel funding from Pfizer and Bayer but unrelated to the current work. The other authors have nothing to disclose.
: No complex statistical methods were necessary for this paper.
: Written informed consent was not required for this study because of the retrospective design and was waived by the Institutional Review Board.
: Institutional Review Board approval was obtained.
: No overlap with prior studies.
:
